Teva’s Actavis will be able to offer a generic alternative to Bausch Health’s Xifaxan (rifaximin) 550mg tablets in the US around two years before the longest-lasting US patent protecting the gastrointestinal drug expires. Under the terms of a patent-litigation settlement that ends proceedings in a Delaware district court, Actavis can market, without royalties, its own approved generic of Xifaxan 550mg from 1 January 2028. Alternatively, from the same date, the generics firm can license restricted supplies of an authorised generic.
Actavis finds a Xifaxan date
Teva’s Actavis will be able to offer a generic alternative to Bausch Health’s Xifaxan (rifaximin) 550mg tablets in the US around two years before the longest-lasting US patent protecting the gastrointestinal drug expires. Under the terms of a patent-litigation settlement that ends proceedings in a Delaware district court, Actavis can market, without royalties, its own approved generic of Xifaxan 550mg from 1 January 2028. Alternatively, from the same date, the generics firm can license restricted supplies of an authorised generic.
More from Generics
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.